Form 4: Adverum CEO's Stock Changes Post-Eli Lilly Merger

Adverum Biotechnologies CEO Laurent Fischer reports significant changes in beneficial ownership following the company's acquisition by Eli Lilly and Company, involving cash and contingent value rights.

Summary

• Laurent Fischer, CEO, President, and Director of Adverum Biotechnologies, Inc., reported changes in his beneficial ownership of company securities.
• The changes occurred on December 9, 2025, coinciding with the effective time of the merger where Eli Lilly and Company acquired Adverum Biotechnologies.
• Under the merger agreement, tendering stockholders received $3.56 per share in cash and one non-tradable contingent value right (CVR) per share.
• Each CVR represents the contractual right to receive up to two contingent cash payments totaling up to $8.91 per CVR upon achievement of specified milestones.
• Restricted Stock Units (RSUs) were cancelled, and holders received cash equal to the Cash Consideration multiplied by the number of shares, plus one CVR per share.
• Performance Stock Units (PSUs) vested 100% due to the change of control and were then cancelled, with holders receiving cash equal to the Cash Consideration multiplied by the number of shares, plus one CVR per share.
• Out-of-the-money stock options (exercise price equal to or greater than the Cash Consideration) were fully vested and then cancelled for no consideration if unexercised.
• Fischer exercised options to acquire 150,000 shares of Common Stock at a price of $4.2 per share.
• Following the transactions, Fischer's direct beneficial ownership of Common Stock became 0 shares, 0 Restricted Stock Units, 0 Performance Stock Units, and 0 Stock Options, indicating full conversion/disposition of his equity holdings in the now private entity.

Sentiment

Score: 7

Explanation: The sentiment is positive for former shareholders due to the acquisition providing immediate cash and potential future value via CVRs. However, the cancellation of out-of-the-money options for no consideration represents a negative for some option holders.

Positives

• The merger provided Adverum Biotechnologies shareholders with immediate cash consideration of $3.56 per share.
• Shareholders also received Contingent Value Rights (CVRs) offering potential additional payments of up to $8.91 per CVR, providing upside potential based on future milestones.
• Performance Stock Units (PSUs) held by the CEO vested 100% due to the change of control, maximizing their value prior to conversion.
• Restricted Stock Units (RSUs) were converted into cash and CVRs, providing liquidity and potential future value.

Negatives

• Stock options with an exercise price equal to or greater than the Cash Consideration ('Out-of-the-Money Options') were cancelled for no consideration if unexercised, resulting in a loss of potential value for holders of these options.

Risks

• The Contingent Value Rights (CVRs) are non-tradable and their value is contingent upon the achievement of specified milestones, meaning the full $8.91 per CVR is not guaranteed and may not be realized.
• The company is now a wholly-owned subsidiary of Eli Lilly and Company, meaning its common stock is no longer publicly traded, limiting liquidity for former shareholders who did not tender their shares or whose equity awards converted to CVRs.

Future Outlook

Adverum Biotechnologies, Inc. is now a wholly-owned subsidiary of Eli Lilly and Company. The future financial performance and strategic direction will be integrated within Eli Lilly. The realization of the full value of the Contingent Value Rights (CVRs) depends on the achievement of specified future milestones.

Industry Context

This transaction reflects a common trend in the biotechnology and pharmaceutical industry where larger pharmaceutical companies acquire smaller biotech firms to expand their pipeline, gain access to innovative therapies, or consolidate market positions. The use of Contingent Value Rights (CVRs) is a frequent mechanism in such acquisitions, allowing the acquirer to mitigate risk while providing potential upside to the acquired company's shareholders based on the future success of specific assets or programs.

Comparison to Industry Standards

• The cash-plus-CVR structure is a common acquisition model in the biotech sector, similar to deals seen with companies like Celgene (acquired by Bristol-Myers Squibb) or Spark Therapeutics (acquired by Roche), where CVRs are used to bridge valuation gaps and share future risks/rewards.
• The immediate cash consideration of $3.56 per share provides a baseline value, while the potential $8.91 per CVR offers a significant contingent premium, indicating a valuation structure that balances immediate return with future performance incentives, typical for clinical-stage biotech assets.

Corporate Governance

Related Party Transactions

• The entire merger transaction between Adverum Biotechnologies, Inc. and Eli Lilly and Company (through its subsidiary) constitutes a related party transaction in the context of the company's change of control.

Stakeholder Impact

• Shareholders: Received cash consideration and Contingent Value Rights (CVRs) for their shares, providing liquidity and potential future upside.
• Employees (holding equity awards): Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) were converted into cash and CVRs, while out-of-the-money stock options were cancelled.
• Company: Became a wholly-owned subsidiary of Eli Lilly and Company, ceasing to be an independent publicly traded entity.

Next Steps

• Monitoring the achievement of specified milestones that would trigger payments under the Contingent Value Rights (CVR) agreement.

Key Dates

Keywords

Adverum Biotechnologies, Eli Lilly, Merger, Acquisition, Form 4, Insider Transaction, Contingent Value Rights, CVR, Stock Options, Restricted Stock Units, Performance Stock Units, Beneficial Ownership